Kane Biotech Inc. (CVE:KNE – Get Free Report) traded down 10.7% on Tuesday . The stock traded as low as C$0.13 and last traded at C$0.13. 113,000 shares changed hands during mid-day trading, a decline of 15% from the average session volume of 132,867 shares. The stock had previously closed at C$0.14.
Kane Biotech Price Performance
The company has a 50-day moving average price of C$0.14 and a two-hundred day moving average price of C$0.14. The company has a debt-to-equity ratio of 1,164.24, a current ratio of 0.82 and a quick ratio of 0.39. The company has a market cap of C$16.56 million, a PE ratio of -4.67 and a beta of 0.54.
Kane Biotech (CVE:KNE – Get Free Report) last issued its earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$0.62 million during the quarter.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Articles
- Five stocks we like better than Kane Biotech
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Why Lennar Stock Could Be the Best Play in the Housing Market
- The Role Economic Reports Play in a Successful Investment Strategy
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Investing In Automotive Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
